Absent Federal Action, States Take The Lead On Curbing Drug Costs
Congress has yet to take substantive action on this growing consumer concern, but a number of states are flexing their cost-control muscle.
Drug Costs
581 - 600 of 698 Results
-
-
Out-Of-Pocket Costs Often Keep Pricey New Cholesterol Drugs Out Of Reach, Study Finds
Research published this week by JAMA Cardiology analyzed pharmacy claims data related to a new class of cholesterol-lowering drugs.
-
Right After Trump Blamed High Drug Prices On Campaign Cash, Drugmakers Gave More
At a political rally in March, President Donald Trump said drug prices are 鈥渙utrageous鈥 and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
By Sydney Lupkin and Elizabeth Lucas -
News Analysis
Everyone Says We Must Control Exorbitant Drug Prices. So, Why Don鈥檛 We?
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
By Jay Hancock -
High On Drugs? Anthem Cites Soaring Drug Costs To Justify 35% Rate Hike in California
The company鈥檚 drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
听By Chad Terhune -
The Orphan Drug Machine
FDA Moves To Guard Against Abuse Of 鈥極rphan Drug鈥 Program
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of 鈥渙rphan drugs鈥 while closing a loophole that allowed drugmakers to skip pediatric testing.
-
Facebook Live: The Prescription Drug Pricing Pipeline
In this Facebook Live, KHN鈥檚 Julie Appleby talks with Stephanie Stapleton and answers readers鈥 questions about the prescription drug pricing pipeline and the industry stakeholders who have a role in what you pay.
-
鈥楤reakthrough鈥 Leukemia Drug Also Portends 鈥楺uantum Leap鈥 In Cost
A genetically altered cancer drug, based on CAR T-cell therapies, could be a big success with leukemia patients but at a staggering cost.
By Liz Szabo -
Podcast: ‘What The Health?’ Why Is It So Difficult To Control Drug Prices?
In this episode of 鈥淲hat the Health?鈥 Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Act鈥檚 marketplaces and the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.
-
Climbing Cost Of Decades-Old Drugs Threatens To Break Medicaid Bank
Medicaid spent billions more in 2016 than the year before on decades-old prescription drugs, including many generics, a Kaiser Health News data analysis shows.
-
Hospitals Slashed Use Of Two Heart Drugs After Huge Price Hikes
Hospital use of two popular heart medicines, nitroprusside and isoproterenol, dramatically dropped after the prices for both soared.
-
Taking A U-Turn On Benefits, Big Employers Vow To Continue Offering Health Insurance
Three years ago, only about a quarter of the nation鈥檚 large employers were very confident they would have a health plan in 10 years. That number has now risen to 65 percent.
By Jay Hancock -
Denial, Appeal, Approval 鈥 An Adult鈥檚 Thorny Path To Spinraza Coverage
The FDA granted approval for Spinraza in late December for use on children and adults with spinal muscular atrophy. Insurance coverage is mostly focused on infants and children.
-
Drug Puts A $750,000 鈥楶rice Tag On Life鈥
The high cost of Spinraza, a new and promising treatment for spinal muscular atrophy, highlights how the cost-benefit analysis insurers use to make drug coverage decisions plays out in human terms.
-
Follow The Money: Drugmakers Deploy Political Cash As Prices And Anger Mount
Embattled opioid seller Mallinckrodt is one of many pharmaceutical companies boosting political contributions and lobbying on Capitol Hill.
-
REPEAL & REPLACE WATCH
Whichever Way ‘Repeal And Replace’ Blows, Pharma Is Due For Windfall
A little-noticed provision in President Donald Trump鈥檚 executive order on drug prices may offer a clue to why Big Pharma hasn鈥檛 opposed a bill that could bleed their balance sheets of millions of patients.
By Emily Kopp -
Exclusive: White House Task Force Echoes Pharma Proposals
Documents examined by Kaiser Health News shed light on the workings of the Trump administration's 鈥淒rug Pricing and Innovation Working Group."
By Emily Kopp -
Former Pharma Reps鈥 New Mission: To School Docs On High Drug Costs
One insurer is turning the tables on drugmakers with what may be a new job category: a sales force for cost-effective medicine.
By Jay Hancock -
Daylight On Diabetes Drugs: Nevada Bill Would Track Insulin Makers鈥 Profits
With the cost of medications up 300 percent in the past decade, supporters see this as a first step to rein in prices.
By Emily Kopp -
Drug Rebates Reward Industry Players 鈥 And Often Hurt Patients
A new JAMA study examines how drug rebates can direct money to middlemen and force Medicare patients to cough up more money.